LifeCord

Company Overview

Snapshot

Founded in September 2023, LifeCord operates with 1–10 employees. The company has raised $1.3M across two funding rounds from three investors. In April 2025, LifeCord secured funding from lead investor Edge Medical Ventures.

Business overview

LifeCord is a Health Tech & Life Sciences company focused on developing a transfemoral mitral chordal repair system. This innovative medical device addresses the significant clinical challenge of mitral regurgitation, providing a less invasive alternative to traditional open-heart surgery. The company operates within the medical devices sector, specifically targeting medical treatment and therapeutics, and serves the healthcare provider market.

Strategic signal

In November 2024, news highlighted LifeCord's mitral chordal repair solution as a promising alternative to open-heart surgery. This signals a significant advancement in cardiovascular treatment, potentially offering a less invasive and safer option for patients with mitral regurgitation, and positions LifeCord as a key innovator in the medical device industry.

Company Intelligence Q&A

What is LifeCord's primary focus?

LifeCord is developing a transfemoral mitral chordal repair system designed to address mitral regurgitation, offering an alternative to open-heart surgery.

When was LifeCord founded?

LifeCord was founded in September 2023.

How much capital has LifeCord raised to date?

LifeCord has raised a total of $1.3M across two funding rounds.

Which investors participated in LifeCord's April 2025 funding round?

In April 2025, LifeCord secured funding from lead investor Edge Medical Ventures.

Which investors participated in LifeCord's April 2024 funding round?

In April 2024, LifeCord received funding from the Israel Innovation Authority and MEDX Xelerator.